Namocell Inc., a leading provider of single cell sorting and dispensing platforms has entered into a collaboration with Takara Bio and HepaTx to perform single cell isolation and analysis on HepaTx’s unique hepatocyte-like cells (iHeps) developed from adipose tissue-derived stromal cells (ASCs).
MOUNTAIN VIEW, CALIF. (PRWEB) FEBRUARY 20, 2020
Namocell Inc., a leading provider of single cell sorting and dispensing platforms, announced today that it has entered into a collaboration with Takara Bio and HepaTx to use Namocell’s Single Cell Dispensers to perform single cell isolation on HepaTx’s unique hepatocyte-like cells (iHeps) developed from adipose tissue-derived stromal cells (ASCs), and characterize them by single cell RNA-seq (scRNA-seq) using Takara Bio’s SMART-seq® technology.
“We are excited to collaborate with Takara and HepaTx to leverage our unique single cell sorting and dispensing platform to support HepaTx’s innovative stem cell- based cell therapy that could revolutionize the treatment of late-stage liver diseases by replacing liver transplants. Namocell’s fast and gentle sorting and dispensing technology is enabling superior cell isolation for single cell analysis,” said Dr. Junyu Lin, CEO of Namocell.
“We are excited to be working with Namocell and HepaTx and contribute to the development of an innovative clinical solution. Leveraging our SMART-seq technology with Namocell’s single cell dispenser is an ideal match for performing plate based single cell RNA-seq enabling researchers to perform full length sequence analysis on single cells providing a deeper view into gene expression and cellular differentiation,” said Dr. Suvarna Gandlur, Associate Director of Next Generation Sequencing at Takara Bio USA.
“Namocell’s and Takara’s single cell technologies will help us advance our cell therapy platform to the clinic more quickly by enabling a deep molecular view of our development product. This will help us reach our goal of providing a scalable solution that can address clear clinical needs and provide better alternatives to liver transplants for patients,” said Dr. Eric Schuur, CEO of HepaTx.
Namocell provides innovative single cell sorting and dispensing platforms to empower single cell research and therapeutics development. Namocell’s single cell dispensers are the fastest and easiest way to identify and isolate single cells, and enable users to accomplish single cell sorting and dispensing in one step in a way that is gentle to live cells. We serve researchers and scientists in a wide range of applications, including single cell genomics, cell line development, CRISPR, cell therapy, stem cell, monoclonal antibody development, rare cell isolation, and synthetic biology. Learn more at http://www.namocell.com.
HepaTx is a regenerative medicine company developing new types of stem cell-based treatments for patients with late stage liver disease, a highly underserved and cost intensive market. HepaTx’s proprietary process, licensed from Stanford and well protected by licensed IP, differentiates adipose stromal cells obtained from discarded lipoaspirate into functional hepatocytes. These hepatocytes are directly infused into the liver where they regenerate liver function. To learn more, visit our website, Hepatx.com and follow us on Twitter, @hepatx.
About Takara Bio USA
Takara Bio USA, Inc. (TBUSA; formerly Clontech Laboratories, Inc.) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for life science applications, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.
Namocell’s and Takara’s single cell technologies will help us advance our cell therapy platform to the clinic more quickly by enabling a deep molecular view of our development product